Quick answer — Require four things of a pharma translation platform: a generated audit trail, version binding to the source, enforced controlled vocabulary, and a deployment posture your quality function will accept. Output quality is not the differentiator.
The demo tells you nothing
Every vendor renders a patient leaflet well. None fails that test, and it is therefore not a test.
What separates them is whether a quality assurance lead will sign off on the system itself, which is a different question asked by different people and usually asked too late.
The four requirements
A generated audit trail. Not an export, not a report somebody assembles. The record of who approved what, when and against which source should be a by-product of doing the work.
Version binding. Every translation tied to a source version, so an amendment marks its translations stale rather than leaving them silently wrong.
Enforced terminology. Controlled vocabularies that the system refuses to improve. A glossary that a model can override is decoration. A deployment posture quality will accept. Where content is processed, what is retained, whether a validated environment is available. This decides the shortlist and it is rarely raised in the first meeting.
Validation is the question behind all four
A system touching regulated content may need qualifying. Ask what documentation the vendor supplies for that, because assembling it yourself costs more than the licence.
Format coverage matters more than in other industries
Labelling artwork, structured dossier modules, infographics, validated e-learning. A text-only tool covers a minority of pharma content, and image translation plus document translation is what closes the gap.
Where to start
Bring quality assurance into the first vendor meeting rather than the fourth.
AI for pharma covers the content split.
FAQ
What separates pharma translation platforms? Not output quality, which is uniformly good. A generated audit trail, version binding to the source, enforced controlled vocabulary and an acceptable deployment posture are where they differ.
What makes an audit trail acceptable? That it is generated rather than assembled. A record of who approved what, when and against which source version should be a by-product of the work, not an export somebody compiles afterwards.
Can a glossary be advisory in pharma? No. A controlled vocabulary that a model is allowed to override is decoration. The system has to refuse improvements to MedDRA terms, international non-proprietary names and dosage forms.
When should quality assurance be involved in vendor selection? In the first meeting rather than the fourth. Whether a quality lead will sign off on the system decides the shortlist, and raising it late wastes the whole evaluation.
